-
Electronic (PDF)
-
Site License
-
Enterprisewide
J&J and Pharmacyclics Enter Licensing Deal on PCI-32765 Development
GlobalData, January 2012, Pages: 4
J&J and Pharmacyclics Enter Licensing Deal on PCI-32765 Development - Deal Analysis from GlobalData
Summary
The report is an essential source of information and analysis on the deal PCI-32765 and the rationale of the deal. The report provides insights on the regulatory and development milestone payments between J&J and Pharmacyclies. Most importantly, the report provides valuable insights on the tyrosine kinase class of products
Scope
The report is an essential source of information on -
- Analysis on the deal of PCI-32765
- Rationale of the deal
- Importance and role of PCI-32765 in hematological malignancies
- Insights on the tyrosine kinase class of products
- Insights on the regulatory and development milestone payments between J&J and Pharmacyclies
Reasons to buy
- Enhance your decision making capabilities in product licensing
- Develop business strategies by identifying the key opportunities with the Btk class of inhibitors.
- Develop and design your in-licensing and out-licensing strategies through the review of real scenarios
- Enahnce your research and development capabilities by identifying the new disease targets associated Btk inhibitor drugs and increase your druggable targets across therapy areas and indications
- How to understand the licensing milestone payments by stage of clinical development? – Identify, understand and capitalize
1
1
1.1 List of Tables
1.2 List of Figures
2 Summary
2.1 Introduction
3 J&J and Pharmacyclics Enter Licensing Deal on PCI-32765 Development
3.1 PCI-32765 and Btk Inhibitors
3.2 Deal Terms and Estimation of Milestones by Clinical Phase
4 Appendix
4.1 Methodology
4.1.1 Coverage
4.1.2 Secondary Research
4.1.3 Primary Research
4.1.4 Expert Panel Validation
4.2 Contact Us
4.3 Disclaimer
1.1 List of Tables
Table 1: Summary of PCI-32765 deal terms
1.2 List of Figures
Figure 1: Bruton tyrosine kinase inhibitors and their structures
Figure 2: Announced milestones of the deal ($m)
Figure 3: Estimated milestones of the deal ($m)
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
